Novel therapeutic approaches to the treatment of metastatic breast cancer

Cancer Treatment Reviews

Volumn 36, Issue 1, 2010, Pages 33-42

  Fernández, Yolanda ^a   Cueva, Juan ^b   Palomo, Andrés G ^c   Ramos, Manuel ^d   de Juan, Ana ^e   Calvo, Lourdes ^f   García Mata, Jesús ^g   García Teijido, Paula ^a   Peláez, Ignacio ^h   García Estévez, Laura ⁱ  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL DE LEÓN   (Spain)

^d Cent Oncol Reg   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g Servizo Galego de Saúde   (Spain)

^h HOSPITAL DE CABUEÑES   (Spain)

ⁱ Centro Integral Oncologico Clara Campal   (Spain)

Author keywords

Cytotoxic; Metastatic breast cancer; Novel; Targeted

Indexed keywords

AFINITOR; ANASTROZOLE; ANTHRACYCLINE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; ERIBULIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IXABEPILONE; LAPATINIB; NAVELBINE; PACLITAXEL; PAZOPANIB; PEMETREXED; PERTUZUMAB; PLACEBO; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TRABECTEDIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CYTOTOXICITY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; LIVER CANCER; LIVER DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 74649085655     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.10.001     Document Type: Review

References (99)

1. Martin M., Mahillo E., Llombart-Cussac A., et al. The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Clin Transl Oncol 8 (2006) 508-518
2. Chia S.K., Speers C.H., D'Yachkova Y., et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110 (2007) 973-979
3. Gueth U., Huang D.J., Schoetzau A., Holzgreve W., and Wight E. Systemic therapy of metastatic breast cancer: the truth beyond the clinical trials. Oncology 76 (2009) 247-253
4. Gligorov J., and Lotz J.P. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat 112 Suppl. 1 (2008) 53-66
5. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33 (2006) S2-S5
6. Cortázar P, Johnson JR, Justice R, Pazdur R. Metastatic breast cancer (MBC): FDA approval overview. In: ASCO meeting abstracts, vol. 26; 2008. p. 1013.
7. Andre F., Slimane K., Bachelot T., et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22 (2004) 3302-3308
8. Muss H.B., Case L.D., Richards II F., et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325 (1991) 1342-1348
9. Falkson G., Gelman R.S., Pandya K.J., et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16 (1998) 1669-1676
10. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000;18:3115-24.
11. Nooij M.A., de Haes J.C., Beex L.V., et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists' preferences. Eur J Cancer 39 (2003) 614-621
12. Stockler M., Wilcken N., and Coates A. Chemotherapy for advanced breast cancer - how long should it continue?. Breast Cancer Res Treat 81 Suppl. 1 (2003) S49-S52
13. Alba E, Ruiz-Borrego M, Martin M, et al. Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. In: ASCO meeting abstracts, vol. 25; 2007. p. 1007.
14. Gennari A, Sormani M, Bruzzi P, et al. A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). In: ASCO meeting abstracts, vol. 26; 2008. p. 1067.
15. Ejlertsen B., Pfeiffer P., Pedersen D., et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A (1993) 527-531
16. Coates A., Gebski V., Bishop J.F., et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317 (1987) 1490-1495
17. Gennari A., Amadori D., De Lena M., et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24 (2006) 3912-3918
18. Gennari A., Sormani M., Bruzzi P., et al. A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 26 Suppl. 15 (2008) 1067
19. Longley D.B., and Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 205 (2005) 275-292
20. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
21. Pronzato P. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. Drugs 68 (2008) 139-146
22. Perez E.A., Lerzo G., Pivot X., et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25 (2007) 3407-3414
23. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25 (2007) 5210-5217
24. Bennouna J., Delord J.P., Campone M., and Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 14 (2008) 1625-1632
25. Campone M., Cortes-Funes H., Vorobiof D., et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 95 (2006) 1161-1166
26. Henderson I.C., and Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 7 (2007) 919-943
27. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005) 7794-7803
28. Roy V., LaPlant B.R., Gross G.G., Bane C.L., and Palmieri F.M. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20 (2009) 449-453
29. Cohen M.H., Johnson J.R., Wang Y.C., Sridhara R., and Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10 (2005) 363-368
30. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
31. Miles D.W., Smith I.E., Coleman R.E., Calvert A.H., and Lind M.J. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37 (2001) 1366-1371
32. Llombart-Cussac A., Martin M., Harbeck N., et al. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 13 (2007) 3652-3659
33. Paridaens R., Dirix L., Dumez H., et al. Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. Clin Breast Cancer 7 (2007) 861-866
34. Gomez H.L., Santillana S.L., Vallejos C.S., et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 12 (2006) 832-838
35. O'Shaughnessy J.A., Clark R.S., Blum J.L., et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6 (2005) 143-149
36. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D 2006;7:317-28.
37. Zelek L., Yovine A., Brain E., et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94 (2006) 1610-1614
38. Vahdat L.T., Pruitt B., Fabian C.J., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 34 (2009) 45-67
39. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 Receptor and breast cancer: ten years of targeted Anti-HER-2 therapy and personalized medicine. Oncologist 2009:theoncologist.2008-0230.
40. Petrelli F., Cabiddu M., Cazzaniga M.E., Cremonesi M., and Barni S. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 13 (2008) 373-381
41. Cancello G., Montagna E., D'Agostino D., et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 10 (2008) R60
42. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
43. Metro G., Mottolese M., and Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 9 (2008) 2583-2601
44. Carlson R.W., Allred D.C., Anderson B.O., et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7 (2009) 122-192
45. Gligorov J., Azria D., Namer M., Khayat D., and Spano J.P. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol 64 (2007) 115-128
46. Vukelja S, Rugo H, Vogel C, et al. A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. . In: San Antonio breast cancer symposium; 2008 [abstract 33].
47. McKeage K., and Perry C.M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62 (2002) 209-243
48. Whenham N., D'Hondt V., and Piccart M.J. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 8 (2008) 38-49
49. Nahta R., Hung M.C., and Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64 (2004) 2343-2346
50. Gelmon KA, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. In: ASCO meeting abstracts, vol. 26; 2008. p. 1026.
51. Ciardiello F., Troiani T., Caputo F., et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94 (2006) 1604-1609
52. Cresta S, Perotti A, Merlini L, et al. Combination of paclitaxel and two schedules of gefitinib in patients with metastatic breast cancer. In: ASCO meeting abstracts, vol. 24; 2006. p. 10599.
53. Cristofanilli M., Valero V., Mangalik A., et al. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 26 (2008) 1012
54. Kaur H., Silverman P., Singh D., et al. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 24 (2006) 10623
55. Reid A., Vidal L., Shaw H., and de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43 (2007) 481-489
56. Lin N.U., Dieras V., Paul D., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15 (2009) 1452-1459
57. Gomez H.L., Doval D.C., Chavez M.A., et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26 (2008) 2999-3005
58. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
59. Di Leo A., Gomez H.L., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26 (2008) 5544-5552
60. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. In: ASCO meeting abstracts, vol. 26; 2008. p. 1015.
61. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 trial. In: San Antonio breast cancer symposium; 2008 [abstract 46].
62. Burstein H, Sun Y, Tan A, et al. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. Cancer Res 2009;69(Suppl. 2):73s [abstract 37].
63. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008) 1810-1816
64. Moreno-Aspitia A., Morton R.F., Hillman D.W., et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central cancer treatment group and Mayo clinic trial N0336. J Clin Oncol 27 (2009) 11-15
65. Sloan B., and Scheinfeld N.S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 9 (2008) 1324-1335
66. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. In: ASCO meeting abstracts, vol. 26; 2008. p. 1016.
67. Choueiri T.K. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 9 (2008) 658-671
68. Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). In: ASCO meeting abstracts, vol. 25; 2007. p. 1003.
69. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
70. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 (2008) 2039-2049
71. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
72. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 Suppl 1 (2000) 37-44
73. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
74. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
75. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
76. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
77. Miles D., Chan A., Romieu G., et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol (Meeting Abstracts) 26 (2008) LBA1011
78. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 27 (2009) 1005
79. Marty M., and Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 44 (2008) 912-920
80. Carraway H., and Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6 (2004) 219-224
81. Carpenter JT, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. In: ASCO meeting abstracts, vol. 23; 2005. p. 564.
82. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009:JCO.2008.18.8391.
83. Rowinsky E.K., Youssoufian H., Tonra J.R., et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13 (2007) 5549s-5555s
84. Papenfuss K., Cordier S.M., and Walczak H. Death receptors as targets for anti-cancer therapy. J Cell Mol Med 12 (2008) 2566-2585
85. Finn R.S. Targeting Src in breast cancer. Ann Oncol 19 (2008) 1379-1386
86. Summy J.M., and Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22 (2003) 337-358
87. Orlowski R.Z., and Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 (2008) 1649-1657
88. Roccaro A.M., Vacca A., and Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 1 (2006) 397-403
89. Yang C.H., Gonzalez-Angulo A.M., Reuben J.M., et al. Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17 (2006) 813-817
90. Engel R.H., Brown J.A., Von Roenn J.H., et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 25 (2007) 733-737
91. Schmid P., Kuhnhardt D., Kiewe P., et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 19 (2008) 871-876
92. Lee M.J., Kim Y.S., Kummar S., Giaccone G., and Trepel J.B. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20 (2008) 639-649
93. Luu T.H., Morgan R.J., Leong L., et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14 (2008) 7138-7142
94. Ramaswamy B, Bhalla K, Cohen B, et al. Phase I-II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium trial P7703. In: San Antonio breast cancer symposium; 2008 [abstract 404].
95. Munster P.N., Lacevic M., Schmitt M., et al. Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy. J Clin Oncol (Meeting Abstracts) 26 (2008) 3501
96. Taldone T., Gozman A., Maharaj R., and Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8 (2008) 370-374
97. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009)
98. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. In: ASCO meeting abstracts, vol. 27; 2009. p. 3.
99. 99. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. In: ASCO meeting abstracts, vol. 27; 2009:CRA501.